insulin degludec vs SHR-3167
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
insulin degludec · Tresiba
Marketed by Novo Nordisk
NCT00982644 · Phase 3 · completed
The trial was randomized and actively controlled, with 1,030 participants, but it was not blinded and its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. HbA1c changed by -1.06% with insulin degludec versus -1.19% with insulin glargine, but no statistical comparison is reported, so whether the primary endpoint was met is unclear.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
Reported efficacy
Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52); Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs) (Week 0 to Week 104 + 7 days of follow up): Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97) (unclear)
Result source: NCT00982644
SHR-3167
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06688123 · Phase 2 · completed
The study randomized 275 adults with type 2 diabetes to once-weekly SHR-3167 (two titration schemes) or daily insulin glargine in an open-label, treat-to-target design. Its primary endpoint was change in HbA1c at week 20, a regulator-accepted measure in type 2 diabetes. Hengrui reports HbA1c reductions similar to glargine (differences -0.02% and -0.14%, with both confidence intervals crossing zero), but neither the registry nor the company states a non-inferiority margin, so whether the primary comparison was met cannot be called. The figures are company-reported and not peer reviewed.
Company release of an EASD 2026 late-breaking abstract; not peer reviewed and not posted on the registry.
Next expected readout: December 2026 · NCT07472725 (registry estimate)
Reported efficacy
Change from baseline to week 20 in HbA1c (HemoglobinA1c) (Week 0 to week 20.): Change in HbA1c from baseline to week 20 (primary): least-squares mean -1.37% (SHR-3167 group A, titration step 2 mg) and -1.49% (group B, titration step 1.5 mg) vs -1.35% with insulin glargine U100; differences -0.02% (95% CI -0.20 to 0.16) and -0.14% (95% CI -0.32 to 0.05); 275 randomized. No non-inferiority margin is stated.
Result source: NCT06688123
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin degludec | SHR-3167 |
|---|---|---|
| HbA1c, change | -1.1% vs -1.2%vs IGlarNCT0098264422 other results
| —Trial running · NCT07913061 |
| Body weight, change (kg) | 1.2 vs 3vs Insulin GlargineNCT0250116115 other results
| —Trial running · NCT07913061 |
| HbA1c below 7% | 75.3% vs 35.6%vs Liraglutide or ExenatideNCT01676116 | —Trial running · NCT07913061 |
| Fasting plasma glucose, change | -3.9 vs -3.7vs Insulin GlargineNCT0250116115 other results
| —Trial running · NCT07913061 |
| 3-point MACE (% with event) | —Not posted · NCT05802862 | —Trial running · NCT07913061 |
HbA1c, change
- insulin degludec
- -1.1% vs -1.2%vs IGlarNCT00982644
22 other results
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -1.4% vs -1.6% NCT04795531
- -1.7% vs -1.2% NCT03172494
- -1.2% vs -1.2% NCT03172494
- -1.9% vs -1.1% NCT03175120
- -1.5% vs -1.4% NCT02762578
- -0.1% vs -0.1% NCT03268005
- -1.9% vs -0.7% NCT02911948
- -1.5% vs -1.5% NCT02420262
- -1.8% vs -1.1% NCT01952145
- -1.3% vs -0.4% NCT01676116
- -0.6% vs -0.5% NCT04588259
- -0.1% vs -0.1% NCT01570751
- -1.1% vs -1.1% NCT02648217
- -0.9% vs -0.8% NCT01959529
- -0.9% vs -1.1% NCT00982644
- -0.5% vs -0.5% NCT03078478
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -2.0% vs -1.7% NCT02501161
- -0.5% vs 0% NCT04538352
- SHR-3167
- —Trial running · NCT07913061
Body weight, change (kg)
- insulin degludec
- 1.2 vs 3vs Insulin GlargineNCT02501161
15 other results
- 2.9 vs 1.7 NCT03078478
- 2.9 vs -1 NCT02607306
- 4.1 vs -1 NCT02607306
- 2.3 vs 2.8 NCT04795531
- 0.2 vs -2.5 NCT03172494
- 0.5 vs 2.2 NCT02501161
- -1.4 vs 1.8 NCT01952145
- 1.2 vs 1.1 NCT03268005
- 1.3 vs -2.5 NCT03172494
- -0.7 vs 0.5 NCT03175120
- 2.8 vs 2.2 NCT02762578
- -0.7 vs 0.7 NCT02911948
- -0.9 vs 2.6 NCT02420262
- 2 vs -0.8 NCT01676116
- -8.6 vs 1.4 NCT04538352
- SHR-3167
- —Trial running · NCT07913061
HbA1c below 7%
- insulin degludec
- 75.3% vs 35.6%vs Liraglutide or ExenatideNCT01676116
- SHR-3167
- —Trial running · NCT07913061
Fasting plasma glucose, change
- insulin degludec
- -3.9 vs -3.7vs Insulin GlargineNCT02501161
15 other results
- -2.0 vs -1.4 NCT03078478
- -4.1 vs -2.6 NCT02607306
- -4.0 vs -2.6 NCT02607306
- -3.0 vs -3.0 NCT04795531
- -3.6 vs -1.9 NCT03172494
- -4.0 vs -3.8 NCT02501161
- -3.0 vs -0.6 NCT01676116
- 0.6 vs 0.7 NCT03268005
- -3.5 vs -1.9 NCT03172494
- -3.6 vs -2.8 NCT03175120
- -3.0 vs -1.6 NCT02762578
- -2.8 vs -2.3 NCT02911948
- 0.4 vs 0.2 NCT04588259
- -0.8 vs 0 NCT01570751
- -2 vs -4.4 NCT02648217
- SHR-3167
- —Trial running · NCT07913061
3-point MACE (% with event)
- insulin degludec
- —Not posted · NCT05802862
- SHR-3167
- —Trial running · NCT07913061
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. insulin degludec: 4 of 4 rows · SHR-3167: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin degludec |
|---|---|
| Dropout rate | 21.5%once dailya NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results2% NCT01959529 · Phase 3 0%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 10.9% NCT03336528 · Phase 4 · registry result, not featured evidence — NCT04588259 · Phase 3 · registry result, not featured evidence 2.7% NCT04795531 · Phase 3 · registry result, not featured evidence 6.7%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 4% NCT03175120 · Phase 3 · registry result, not featured evidence — NCT03078478 · Phase 3 · registry result, not featured evidence 2.7% NCT03268005 · Phase 3 · registry result, not featured evidence 4.3% NCT02501161 · Phase 3 · registry result, not featured evidence 2.2% NCT02906917 · Phase 3 · registry result, not featured evidence 8.5%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 7.6%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 0% NCT02911948 · Phase 3 · registry result, not featured evidence 4.8% NCT02773368 · Phase 3 · registry result, not featured evidence 4.2%BID NCT02762578 · Phase 3 · registry result, not featured evidence 0.8% NCT02420262 · Phase 3 · registry result, not featured evidence 7.6%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 2.9%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 10.1% NCT01952145 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination —Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination — NCT01570751 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 2.6%once dailya NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results0% NCT01959529 · Phase 3 —once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination — NCT03336528 · Phase 4 · registry result, not featured evidence — NCT04588259 · Phase 3 · registry result, not featured evidence — NCT04795531 · Phase 3 · registry result, not featured evidence 0.6%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 1.4%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 0.7% NCT03175120 · Phase 3 · registry result, not featured evidence — NCT03078478 · Phase 3 · registry result, not featured evidence — NCT03268005 · Phase 3 · registry result, not featured evidence 0.4% NCT02501161 · Phase 3 · registry result, not featured evidence 0.4% NCT02906917 · Phase 3 · registry result, not featured evidence 2.2%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 2.9%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence — NCT02911948 · Phase 3 · registry result, not featured evidence — NCT02773368 · Phase 3 · registry result, not featured evidence 0.3%BID NCT02762578 · Phase 3 · registry result, not featured evidence 0.4% NCT02420262 · Phase 3 · registry result, not featured evidence 0%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 1%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 2.9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 3.2% NCT01952145 · Phase 3 · registry result, not featured evidence 0.3%Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination —Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination — NCT01570751 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 15.1%once dailya NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results38.6% NCT01959529 · Phase 3 22.5%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 3.7% NCT03336528 · Phase 4 · registry result, not featured evidence 6.7% NCT04588259 · Phase 3 · registry result, not featured evidence 5.1% NCT04795531 · Phase 3 · registry result, not featured evidence 4%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 3.9%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 4.3% NCT03175120 · Phase 3 · registry result, not featured evidence 20.8% NCT03078478 · Phase 3 · registry result, not featured evidence 7% NCT03268005 · Phase 3 · registry result, not featured evidence 11.9% NCT02501161 · Phase 3 · registry result, not featured evidence 6.8% NCT02906917 · Phase 3 · registry result, not featured evidence 4.8%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 6.2%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.9% NCT02911948 · Phase 3 · registry result, not featured evidence 2.9% NCT02773368 · Phase 3 · registry result, not featured evidence 4.4%BID NCT02762578 · Phase 3 · registry result, not featured evidence 4.8% NCT02420262 · Phase 3 · registry result, not featured evidence 3.8%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 6.7%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 3.3%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 1.8% NCT01952145 · Phase 3 · registry result, not featured evidence —Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination 3.1%Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination 2.9% NCT01570751 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | once dailya nasopharyngitis 23.9% headache 13.8% diarrhoea 10.8% NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 23 more resultsonce weekly pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination emergency room visit for bilateral knee pain 1.2% emergency room visit for congestive heart failure 1.2% emergency room visit for wound infection 1.2% NCT03336528 · Phase 4 · registry result, not featured evidence diabetic retinopathy 14.7% hyperlipidaemia 14% upper respiratory tract infection 9.3% NCT04588259 · Phase 3 · registry result, not featured evidence covid-19 4.8% influenza 3.1% diabetic retinopathy 2% NCT04795531 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.7% nasopharyngitis 5.1% diabetic retinopathy 3.4% NCT03172494 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18.4% diabetic retinopathy 7.8% lipase increased 7.5% NCT03172494 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 12.6% lipase increased 12% diabetic retinopathy 11.6% NCT03175120 · Phase 3 · registry result, not featured evidence nasopharyngitis 19% upper respiratory tract infection 18.1% diarrhoea 9% NCT03078478 · Phase 3 · registry result, not featured evidence nasopharyngitis 5.9% NCT03268005 · Phase 3 · registry result, not featured evidence headache 11.5% nasopharyngitis 11.3% diarrhoea 7.7% NCT02501161 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% headache 10.2% back pain 6% NCT02906917 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 33.6% weight increased 7% pharyngitis 5.5% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 38.5% constipation 9.8% diabetic retinopathy 6.2% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 20% diabetic retinopathy 16.2% diarrhoea 14.3% NCT02911948 · Phase 3 · registry result, not featured evidence headache 8.6% viral upper respiratory tract infection 7.7% lipase increased 5.7% NCT02773368 · Phase 3 · registry result, not featured evidence BID upper respiratory tract infection 21.1% diabetic retinopathy 10% viral upper respiratory tract infection 2.5% NCT02762578 · Phase 3 · registry result, not featured evidence nausea 11.1% influenza 7.1% diarrhoea 6.3% NCT02420262 · Phase 3 · registry result, not featured evidence twice daily blood glucose decreased 35.4% upper respiratory tract infection 6.2% pyrexia 3.1% NCT02648217 · Phase 3 · registry result, not featured evidence lipase increased 10% headache 9.3% nasopharyngitis 8.9% NCT01676116 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 1.4% NCT01570751 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 25 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin degludec
show 22 more results
show 2 more results
show 15 more results
+ 111 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin degludec's landscape · SHR-3167's landscape